brainstorm cell therapeutics inc shares were up 13 to 175 after the company said that the us food and drug administration will hold an advisory committee meeting to discuss the companys biologics license application for nurown for the treatment of amyotrophic lateral sclerosis the company said in order to move as quickly as possible it requested that the center for biologics evaluation and research use the fdas file over protest procedure and has filed an amendment to the bla which responds to most of the outstanding questions the fda has posed brainstorm said the fda has provided it with more than one path to a meeting for nurown the meeting would provide an open forum for brainstorm and the fda together with medical experts statisticians and the als community to review all available evidence supporting nurown the stock is down 48 in the past 12 months